FDA Grants Fast Track Designation for MimiVax’s SurVaxM
Device indicated for newly diagnosed glioblastoma.
MimiVax, Inc., a biotechnology company focused on the development of glioblastoma vaccine therapy, announced in a company press release that the FDA has granted fast track designation (FTD) to MimiVax's SurVaxM vaccine being studied for the treatment of newly diagnosed glioblastoma (nGBM). MimiVax is focused on completing the Phase 2b survive study and securing funding necessary to bring SurVaxM through the FDA approval process.
"The receipt of Fast Track Designation affirms the importance of new clinical developments of novel therapies to improve the treatment and outcomes for patients with newly diagnosed glioblastoma," said Michael Ciesielski, CEO, MimiVax. "This designation is a key component in our journey to help patients with glioblastoma to live longer."
Reference: MimiVax Granted Fast Track Designation from FDA for SurVaxM for Newly Diagnosed Glioblastoma. PR Newswire. October 12, 2023. Accessed October 13, 2023. https://www.prnewswire.com/news-releases/mimivax-granted-fast-track-designation-from-fda-for-survaxm-for-newly-diagnosed-glioblastoma-301954795.html
New machine-learning approach could speed precision drug development
The approach, detailed this week in the journal Nature, uses a platform called Molecular Surface Interaction Fingerprinting (MaSIF) to design custom proteins that bind to drug-bound target proteins.
AI-enabled CGM app shows promise for glycemic control, weight management
The broader implications of this study suggest that digital health platforms like January V2 have the potential to play a crucial role in the future of chronic disease management,” the authors write.
